Sign in to view content

Outcomes of Patients with DME and Baseline BCVA 20/50 or Worse or 20/40 or Better Treated with Aflibercept 8 mg and 2 mg in the Phase 2/3 PHOTON Trial

Diana V Do, MD, FASRS

Video
Published 2024

Related

Impact of Race on Vision Outcomes in Ranibizumab-Treated Patients With Diabetic Macular Edema: A Meta-Analysis of 5 Clinical Trials
M. Ali Khan, MD, FACS, FASRS
Annual Meeting Talks
2021
Randomized Trial of Initiating Therapy With Aflibercept, Laser, or Observation for Eyes With Good Vision and Center-Involved DME
Carl W. Baker, MD, FASRS
Annual Meeting Talks
2019
Optical Coherence Tomography Angiography Biomarkers for Predicting Visual Outcomes after Ranibizumab Treatment for Diabetic Macular Edema
Yi-Ting Hsieh, MD
On Demand Cases, Courses, and Papers
2019

Category: Retinal Vascular Disease

See more